Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 biologic product BC008-1A. This product is intended for the treatment of glioblastoma and advanced solid tumors, including non-small cell lung cancer and esophageal cancer.
BC008-1A is a bispecific antibody (BsAb) that targets both programmed-death 1 (PD-1) and T cell immunoglobulin and ITIM domains (TIGIT). Notably, there is no similar product that has been approved for marketing worldwide, making this development a significant step forward in the field of oncology treatments.- Flcube.com
